Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
122
resultados
Última actualización
07/12/2025 [07:04:00]
Resultados 50 a 75 de 122
Resumen de: WO2025230306A1
The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.
Resumen de: WO2025231182A1
The application provides a pharmaceutical composition, which comprises an antiviral peptide conjugate, for the treatment or prevention of a condition or disease associated with a coronaviral infection. The coronavirus includes human coronavirus OC43, human coronavirus HKU1, human coronavirus 229E, human coronavirus NL63, Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, SARS-CoV-2, or any variant thereof. The pharmaceutical composition is designed for, inter alia, intranasal administration.
Resumen de: WO2025231155A2
The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS- COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.
Resumen de: WO2025231364A1
The present disclosure relates to the field of vaccines, as well as preparations, articles of manufacture, and methods of their use in the treatment and/or prevention of diseases (e.g., infectious diseases, cancer, etc.). In certain embodiments, the disease is a coronavirus infection related disease. In certain embodiments, the coronavirus can be a P-coronaviruses (e.g., SARS- CoV-2).
Resumen de: US2025339508A1
Described herein are compositions of recombinant SARS-CoV-2 constructs and particles that can interfere with or block infection of uninfected cells. The compositions and methods described herein are useful for treatment of SARS-Co V-2 infections. The recombinant SARS-CoV-2 construct cannot replicate by itself, but can replicate in the presence of infective SARS-CoV-2 (e.g., replication competent SARS-CoV-2). Thus, the present application in one aspect provides a recombinant SARS-Co V-2 construct (e.g., SARS-CoV-2 TIP) capable of interfering with SARS-CoV-2 replication, wherein the recombinant SARS-CoV-2 construct cannot replicate by itself, and wherein the recombinant SARS-CoV-2 construct can replicate in the presence of SARS-CoV-2.
Resumen de: US2025340957A1
An oligonucleotide, having a 5′ terminus and a 3 terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:60 and SEQ ID NO:77.
Resumen de: KR20250157984A
본 발명은 SARS-CoV-2 B.1.617.2 RBD에 특이적인 단일도메인 항체 및 이의 용도에 관한 것이다. 본 발명의 SARS-CoV-2 B.1.617.2의 스파이크 단백질의 RBD에 특이적으로 결합하는 중쇄 항체 또는 이의 항원 결합 단편은 B.1.617.2 변이에 특이적으로 결합하는 단일도메인 항체를 포함하는 것으로서, 높은 친화도 및 특이성을 바탕으로 바이러스성 질환 치료제 및 진단용 조성물로서 유용하게 사용될 수 있다.
Resumen de: KR20250157983A
본 발명은 SARS-CoV-2 BA.2 RBD에 특이적인 단일도메인 항체 및 이의 용도에 관한 것이다. 본 발명의 SARS-CoV-2 BA.2의 스파이크 단백질의 RBD에 특이적으로 결합하는 중쇄 항체 또는 이의 항원 결합 단편은 BA.2 변이에 특이적으로 결합하고 이를 중화할 수 있는 단일도메인 항체를 포함하는 것으로서, 높은 친화도 및 특이성을 바탕으로 바이러스성 질환 치료제 및 진단용 조성물로서 유용하게 사용될 수 있다.
Resumen de: KR20250156928A
본 발명은 MERS-CoV RBD에 대한 인간 항체 및 이의 용도에 관한 것이다. 본 발명의 항체 또는 그의 항원 결합 단편은 MERS-CoV RBD에 특이적으로 결합하여 MERS-CoV의 감염을 억제할 수 있으며, 본 발명의 이중항체는 서로 다른 에피토프를 가진 2종의 항체 또는 항원 결합 단편을 포함하고, 단일클론항체 및 두 단일클론항체의 조합보다 더 우수한 중화효능을 가지므로 MERS의 치료제로서 유용하게 사용될 수 있다.
Resumen de: MX2025010057A
The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: MX2025010056A
The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, <i>e.g.</i>, to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: MX2025012626A
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: AU2024234602A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: AU2024231716A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.
Resumen de: US2025332220A1
The present invention relates to a method for treating and/or preventing pneumonia, including administering a therapeutically effective amount of cerebral dopamine neurotrophic factor (CDNF) to a subject in need thereof. The pneumonia is caused by infection of influenza A virus or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Resumen de: US2025332170A1
Compositions for and methods of treating lung conditions, such as those associated with elevated cytokines, are described. The methods include administration of vandetanib or a pharmaceutically acceptable salt thereof. Methods of treating COVID-19 via administration of vandetanib or a pharmaceutically acceptable salt thereof are also described. Administration of vandetanib can reduce levels of cytokines that are elevated in subjects suffering from COVID-19 and mitigate or eliminate the cytokine storm associated with severe cases of COVID-19.
Resumen de: US2025332162A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease which may involve combinations of agents. Here we describe combinations of 2, 3 or more drugs wherein the combination inhibits CoV2 replication through one or more mechanisms of action and increases potency of nucleoside and nucleotide analog drugs through inhibition of cellular enzymes involved in purine nucleotide biosynthesis. The combinations may be delivered as individual doses, concurrent dosing, or co-formulation of 2 or more agents. The inventive aspect includes identified components, the ratios among identified components and treatment regimens for reducing morbidity and mortality of CoV2 infection. Further claimed are drug formulations and methods of delivery.
Resumen de: US2025333485A1
This disclosure provides anti-SARS-COV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike(S) protein. The disclosed anti-SARS-COV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-COV-2 variants of concern. The disclosed anti-SARS-COV-2 antibodies represent a therapeutic strategy in protecting from SARS-COV-2 infections.
Resumen de: US2025333806A1
Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.
Resumen de: US2025332247A1
The present disclosure provides a glycoengineered SARS-COV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-COV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.
Resumen de: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Resumen de: AU2024234602A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: US2025332136A1
Described herein is a composition and methods for treating, reducing the symptoms of, or prophylaxis of viral infections, and particularly SARS-CoV-2. The composition enhances delivery of oxygen to the tissues. Also described herein is a composition and methods for treating cancers, particularly, adenocarcinomas, infiltrating ductal adenocarcinoma, metastatic ductal adenocarcinoma, and neuroendocrine tumors. The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors.
Resumen de: US2025333452A1
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection; vaccination against SARS-CoV-2.
Nº publicación: US2025332177A1 30/10/2025
Solicitante:
FRIKHA DORRA [US]
Frikha Dorra
Resumen de: US2025332177A1
A methylene blue COVID-19 composition for treating short-term and long-term COVID-19 symptoms. The methylene blue COVID-19 composition consists of methylene blue and aspirin. The amount of methylene blue in the overall composition is in the range of about 50 mg to 300 mg, while the amount of aspirin in the overall composition is in the range of about 80 mg to 350 mg. The methylene blue COVID-19 composition is formed as a powder that is dissolvable in water or another beverage for patient consumption. The overall composition is used as a treatment for up to about 6 months after testing positive for a COVID-19 infection, in order to effectively treat various symptoms of COVID-19 infections. The methylene blue COVID-19 composition is dissolved in liquid to be a standalone methylene blue COVID-19 solution. In one embodiment, the methylene blue COVID-19 composition is in a pill form.
BOPI
Sede Electrónica
